{"id":"guanfacine-gua","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Dry mouth"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Bradycardia"}]},"_chembl":null,"_dailymed":{"setId":"4b86e1c1-9cbe-d4a9-e063-6294a90a2274","title":"GUANFACINE TABLET, EXTENDED RELEASE [GOLDEN STATE MEDICAL SUPPLY, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively binding to alpha-2A adrenergic receptors in the prefrontal cortex and other brain regions, guanfacine decreases norepinephrine signaling, which improves attention, impulse control, and reduces hyperactivity. This mechanism makes it particularly useful for conditions characterized by executive dysfunction and hyperarousal, such as ADHD and hypertension.","oneSentence":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:36.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07300956","phase":"PHASE4","title":"Treating Young Children With Attention Deficit Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":370},{"nctId":"NCT03980184","phase":"PHASE2","title":"Guanfacine to Improve Substance Use Outcomes in Women","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-01","conditions":"Substance Use Disorders","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Guanfacine (GUA)","genericName":"Guanfacine (GUA)","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}